About this product: In this extraordinary novel, Karen Maitland delivers a dazzling reinterpretation of Chaucer’s Canterbury Tales—an ingenious alchemy of history, mystery, and powerful human drama.
The year is 1348. The Black Plague grips the country. In a world ruled by faith and fear, nine desperate strangers, brought together by chance, attempt to outrun the certain death that is running inexorably toward them.
Each member of this motley company has a story to tell. From Camelot, the relic-seller who will become the group’s leader, to Cygnus, the one-armed storyteller . . . from the strange, silent child called Narigorm to a painter and his pregnant wife, each has a secret. None is what they seem. And one among them conceals the darkest secret of all—propelling these liars to a destiny they never saw coming.
Magical, heart-quickening, and raw, Company of Liars is a work of vaulting imagination from a powerful new voice in historical fiction.
Struggling to Get Your Foot in the Door of Big Companies?
Setting up meetings with corporate decision makers has never been harder. It's almost impossible to get them to pick up the phone. They never return your calls. And if you do happen to catch them, they blow you off right away.
It's time to stop making endless cold calls or waiting for the phone to ring. In today's crazy marketplace, new sales strategies are needed to penetrate these big accounts.
Discover how to: • Target accounts where you have the highest likelihood of success. • Find the names of prospects who can use your offering. • Create breakthough value propositions that capture their attention. • Develop an effective, multi-faceted account-entry campaign. • Overcome obstacles and objections that derail your sale efforts. • Position yourself as an invaluable resource, not a product pusher. • Have powerful initial sales meetings that build unstoppable momentum. • Differentiate yourself from other sellers.
Use these sure-fire strategies to crack into big accounts, shrink your sales cycle and close more business. Check out the Account Entry Toolkit for ideas on how to apply this process to your own unique business.
About this product: The vast majority of small businesses stay small—and not by choice. Only the most savvy and persistent—a tiny one tenth of one percent—break through to annual sales above $250 million. In The Breakthrough Company, Keith McFarland pinpoints how everyday companies become extraordinary, showing that luck is a negligible factor. Rather, breakthrough success turns out to be associated with a clearly identifiable set of strategies and skills that anyone in any business can emulate—from small startup to industry leader.
Encouraged by experts such as business legend Peter Drucker and Good to Great author Jim Collins to identify the drivers that enable a company to push past the entrepreneurial phase, McFarland spent five years building and analyzing the world’s largest growth-company performance database and interviewing more than 1,500 growth-company executives on four continents. His goal was simple: to identify the secrets of breakthrough.
The Breakthrough Company is the result. Winnowing a study pool of more than 7,000 companies down to nine that have made the transition to major-player status, McFarland highlights real-world tools and myth-busting insights that can be used by anyone wanting his or her business to join this exclusive circle. Among the book’s takeaways:
• Common wisdom holds that the founders and core entrepreneurial leaders of a company must step aside for the business to reach the next level. Not true—as long as founders “crown the company” instead of themselves. • It’s not reckless to make ever-escalating bets on your company’s future, even going nose to nose with competitors many times your size. In fact, it turns out that the only safety comes in constantly upping the ante in exactly this way. • A Business Bermuda Triangle does exist, gobbling up companies on the verge of breakthrough. Presented here are three ways to navigate this potentially deadly hazard successfully. • However good you are—or think you are—you can’t do it alone. Learn how to surround your company with networks of outside resources, aka “scaffolding,” and how to enlist the aid of “insultants”—people who are willing to question a firm’s existing assumptions and ways of doing business.
With powerful and specific action steps concluding each chapter—and invaluable advice on virtually every page from business leaders who’ve taken their companies to extraordinary levels of growth and profitability—The Breakthrough Company is one of the most provocative, inspiring, and instructive business books you’ll ever read.
Sgt. Don Malarkey takes us not only into the battles fought from Normandy to Germany, but into the heart and mind of a soldier who beat the odds to become an elite paratrooper, and lost his best friend during the nightmarish engagement at Bastogne.
Drafted in 1942, Malarkey arrived at Camp Toccoa in Georgia and was one of the one in six soldiers who earned their Eagle wings. He went to England in 1943 to provide cover on the ground for the largest amphibious military attack in history: Operation Overlord. In the darkness of D-day morning, Malarkey parachuted into France and within days was awarded a Bronze Star for his heroism in battle. He fought for twenty-three days in Normandy, nearly eighty in Holland, thirty-nine in Bastogne, and nearly thirty more in and near Haugenau, France, and the Ruhr pocket in Germany.
This is his dramatic tale of those bloody days fighting his way from the shores of France to the heartland of Germany, and the epic story of how an adventurous kid from Oregon became a leader of men.
About this product: The Ideal Companion to VALUATION FOURTH EDITION
If you want to get more out of Valuation, Fourth Edition, then pick up the Valuation Workbook. This comprehensive study guide provides you with an invaluable opportunity to explore your understanding of the strategies and techniques covered in the main text, before putting it to work in real-world situations.
This hands-on Workbook: * Walks you through Valuation, Fourth Edition--providing chapter-by-chapter coverage of the core text * Tests your comprehension of the ideas presented throughout, with multiple-choice questions and problems * Offers complete coverage of forecasting short, medium, and continuing value; calculating and interpreting results; real option pricing methods; and much more
Valuation Workbook is filled with a wealth of practical learning exercises and information that will help you understand and apply the proven principles found in Valuation, Fourth Edition.
About this product: Many Americans have wondered why prescription drugs have become so expensive while advertising for those drugs seems to grow exponentially. Former New England Journal of Medicine Editor Marcia Angell has some answers. The pharmaceutical industry, according to Angell, is fraught with corruption and doing a disservice to customers, the federal government, and to the medical establishment itself. In The Truth About the Drug Companies, Angell explains how a huge portion of the revenue generated by "Big Pharma" goes not into research and development but into aggressive marketing campaigns to sell their product. She describes how, even though the drug companies claim that it costs them an average of 802 million dollars per drug to develop new medicines, that figure is obscenely inflated since it factors in marketing as well as expected interest the company would have received had they invested the money in the open market. Meanwhile, Angell says, most of the R & D work is done by colleges and universities funded by the government. There are also problems with the drugs themselves, Angell indicates, since a majority are "me-too drugs", slightly modified versions of existing products which meant to address concerns of consumers most likely to spend money on pharmaceuticals. Thus, the market is filled with remarkably similar drugs to treat depression and high cholesterol while potentially life-saving medicines for diseases afflicting third-world countries are discontinued because they aren't profitable. In the books most damning passage, Angell tells of the high-priced junkets offered to doctors, ostensibly offered as educational opportunities that seem to constitute little more than bribes. The prognosis for reform is a grim one, Angell indicates, due to the massive cash reserves and lobbying efforts of "Big Pharma." Indeed, that lobby was hard at work trying to discredit her claims immediately upon the book's publication. But for anyone who's paid a pharmacy bill, The Truth About the Drug Companies is a fascinating read. --John Moe
About this product: Readers expecting something zany, something crudely humorous from Steve Martin's second novel, The Pleasure of My Company, will discover much greater riches. While the book has a sense of humor, Martin moves everywhere with a gentler, lighter touch in this elegant little fiction that verges on the profound and poetic.
Daniel Pecan Cambridge is the narrator and central consciousness of the novel (actually a novella). Daniel, an ex-Hewlett-Packard communiqué encoder, is a savant whose closely proscribed world is bounded on every side by neuroses and obsessions. He cannot cross the street except at driveways symmetrically opposed to each, and he cannot sleep unless the wattage of the active light bulbs in his apartment sums to 1,125. Daniel's starved social life is punctuated by twice-weekly visits from a young therapist in training, Clarissa; by his prescription pick-ups from a Rite Aid pharmacist, Zandy; and by his "casual" meetings with the bleach-blond real estate agent, Elizabeth, who is struggling to sell apartments across the street. But Daniel's dysfunctional routines are shattered one day when he becomes entangled in the chaos of Clarissa's life as a single mother. Taking care of Clarissa's tiny son, Teddy, Daniel begins to emerge from the safety of logic, magic squares, and obsessive counting.
Martin's craftsmanship is remarkable. The tightly packed novella paints rich portraits with restraint and balance, including nothing extraneous to Daniel's world. The book does not try for pyrotechnics but is contented with a Zen-like simplicity in both prose and plot. Avoiding the crushing bleakness of much contemporary fiction, Martin insists through Daniel--a man haunted by horrors of his own making--that there is possibility for compassion, that broken lives can actually be healed. --Patrick O'Kelley
About this product: Penzler Pick, March 2002: Robert Littell, long known as one of the best writers of fiction about the Cold War, is not as well known as John le Carré or the great Charles McCarry, but nevertheless has a devoted following among serious aficionados of the literary spy novel. His latest book, which runs close to 900 pages and covers the years 1950 to 1995, is an ambitious one that is destined to become the definitive novel about the CIA.
The historical events of that crucial period are well known to most of us. The end of World War II and the division of Germany into sectors by the Allies laid the groundwork for the Cold War and the rise of the OSS, a wartime branch of the American government, into one of the most powerful tools of intelligence.
The involvement of that agency in the defection of Burgess and MacLean from Britain to the Soviet Union; the Suez Canal crisis, which ended Britain's role as a superpower; the Bay of Pigs fiasco and the Cuban Missile Crisis; the arming of rebels in Afghanistan to repel the encroaching Soviet forces; the Gulf War--all are well documented here.
All these events, which had such major consequences for our own history and that of the world, were well known to, organized by, or played out with the full cooperation of the CIA. These, as well as such minor events as defections on both sides, are the backdrop to this novel which stars a large cast of characters who we get to know as young men and women recruited while still in college. Their personal and public lives are followed as they rise through the ranks of the Company, and we know that one of them is a mole. We don't know who it is any more than the CIA does, and it will take years to unmask the traitor.
In the meantime, we have become involved not only with Littell's fictional characters, but also with some of the real people who inhabited that world: William F. Buckley Jr., G. Gordon Liddy, William Casey--and we are privy to conversations in both the Kennedy and Reagan Oval Offices.
We also know by the end of this exciting story that the fight is not always the good fight. Compromises are made, mistakes happen, and pragmatism wins out over idealism. We do not live in a perfect world, but it's the only one we have and it is that way because of the events in this book. Don't let its size deter you. This is nothing less than a stunning historical document. --Otto Penzler
About this product: In this latest, widely praised addition to the beloved No. 1 Ladies’ Detective Agency series, the charming and ever-resourceful Precious Ramotswe finds herself faced with new challenges—and intriguing surprises.
Precious is busier than usual at the detective agency when she discovers an intruder in her house on Zebra Drive—and perhaps even more baffling--a pumpkin on her porch. Her associate, Mma Makutsi, also has a full plate. She's taken up dance lessons, only to be partnered with a man with two left feet. And at Tlokweng Road Speedy Motors, where Mr J.L.B. Matekoni is already overburdened with work, one of his apprentices has run off with a wealthy older woman. But what finally rattles Mma Ramotswe’s normally unshakable composure is a visitor who forces her to confront a difficult secret from her past.
About this product: Five years ago, Jim Collins asked the question, "Can a good company become a great company and if so, how?" In Good to Great Collins, the author of Built to Last, concludes that it is possible, but finds there are no silver bullets. Collins and his team of researchers began their quest by sorting through a list of 1,435 companies, looking for those that made substantial improvements in their performance over time. They finally settled on 11--including Fannie Mae, Gillette, Walgreens, and Wells Fargo--and discovered common traits that challenged many of the conventional notions of corporate success. Making the transition from good to great doesn't require a high-profile CEO, the latest technology, innovative change management, or even a fine-tuned business strategy. At the heart of those rare and truly great companies was a corporate culture that rigorously found and promoted disciplined people to think and act in a disciplined manner. Peppered with dozens of stories and examples from the great and not so great, the book offers a well-reasoned road map to excellence that any organization would do well to consider. Like Built to Last, Good to Great is one of those books that managers and CEOs will be reading and rereading for years to come. --Harry C. Edwards
BOOK
